B. Riley Keeps Buy on 4D Molecular After EyePoint’s Phase 3 Miss
4D Molecular gains support as B. Riley views EyePoint’s Phase 3 setback as favorable for its lead gene therapy candidate 4D-150.
/ 6 items
#OCUL↓
FDA Clears Path for AXPAXLI: Ocular Therapeutix Targets Late 2026 NDA Submission
Ocular Therapeutix has reached alignment with the FDA to submit the AXPAXLI NDA for wet AMD in Q4 2026, based on SOL-1 data and interim SOL-R safety results. Topline SOL-R data now expected in Q1 2028.
Ocular's Axpaxli Beats Eylea in Trial — But Is It Enough to Win Over a Skeptical Market?
Ocular Therapeutix's (OCUL) Axpaxli outperformed a low dose of Regeneron's Eylea in a late-stage wet AMD trial — but narrower-than-expected margins sent shares crashing 27%, raising serious doubts about its commercial future.
Sanofi Pursues Enhanced Bid for US Biotech Ocular Therapeutix
French pharma giant Sanofi is preparing an improved takeover offer for Ocular Therapeutix after its initial $16-per-share proposal was rejected by the biotech's board.
Ocular Therapeutix Stock Jumps 27% on Accelerated Drug Approval Plans
Ocular Therapeutix (OCUL) shares surge 27% after announcing plans to fast-track FDA submission for Axpaxli, a promising new treatment for wet age-related macular degeneration affecting millions.
Big Boost for Ocular Therapeutix Stock and Drug Forecast
Piper Sandler raised Ocular Therapeutix stock target to $31 and boosted the AXPAXLI sales forecast to $3.2B due to promising eye drug trial data.